146 related articles for article (PubMed ID: 38153320)
21. Different dosage regimens of zuranolone in the treatment of major depressive disorder: A meta-analysis of randomized controlled trials.
Lian J; Lin Z; Li X; Chen G; Wu D
J Affect Disord; 2024 Jun; 354():206-215. PubMed ID: 38479510
[TBL] [Abstract][Full Text] [Related]
22. Indirect comparisons of relative efficacy estimates of zuranolone and selective serotonin reuptake inhibitors for postpartum depression.
Meltzer-Brody S; Gerbasi ME; Mak C; Toubouti Y; Smith S; Roskell N; Tan R; Chen SS; Deligiannidis KM
J Med Econ; 2024; 27(1):582-595. PubMed ID: 38523596
[TBL] [Abstract][Full Text] [Related]
23. The efficacy and safety of some new GABAkines for treatment of depression: A systematic review and meta-analysis from randomized controlled trials.
Zou J; Yang L; Yang G; Gao J
Psychiatry Res; 2023 Oct; 328():115450. PubMed ID: 37683318
[TBL] [Abstract][Full Text] [Related]
24. Preclinical characterization of zuranolone (SAGE-217), a selective neuroactive steroid GABA
Althaus AL; Ackley MA; Belfort GM; Gee SM; Dai J; Nguyen DP; Kazdoba TM; Modgil A; Davies PA; Moss SJ; Salituro FG; Hoffmann E; Hammond RS; Robichaud AJ; Quirk MC; Doherty JJ
Neuropharmacology; 2020 Dec; 181():108333. PubMed ID: 32976892
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of levomilnacipran sustained release 40 mg, 80 mg, or 120 mg in major depressive disorder: a phase 3, randomized, double-blind, placebo-controlled study.
Asnis GM; Bose A; Gommoll CP; Chen C; Greenberg WM
J Clin Psychiatry; 2013 Mar; 74(3):242-8. PubMed ID: 23561229
[TBL] [Abstract][Full Text] [Related]
26. The efficacy of zuranolone in postpartum depression and major depressive disorder: a review & number needed to treat (NNT) analysis.
Cha DS; Kleine N; Teopiz KM; Di Vincenzo JD; Ho R; Galibert SL; Samra A; Zilm SPM; Cha RH; d'Andrea G; Gill H; Ceban F; Meshkat S; Wong S; Le GH; Kwan ATH; Rosenblat JD; Rhee TG; Mansur RB; McIntyre RS
Expert Opin Pharmacother; 2024; 25(1):5-14. PubMed ID: 38164653
[TBL] [Abstract][Full Text] [Related]
27. Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder.
Trivedi MH; Pigotti TA; Perera P; Dillingham KE; Carfagno ML; Pitts CD
J Clin Psychiatry; 2004 Oct; 65(10):1356-64. PubMed ID: 15491239
[TBL] [Abstract][Full Text] [Related]
28. A comparison of initial duloxetine dosing strategies in patients with major depressive disorder.
Whitmyer VG; Dunner DL; Kornstein SG; Meyers AL; Mallinckrodt CH; Wohlreich MM; Gonzales JS; Greist JH
J Clin Psychiatry; 2007 Dec; 68(12):1921-30. PubMed ID: 18162024
[TBL] [Abstract][Full Text] [Related]
29. Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial.
Rickels K; Athanasiou M; Robinson DS; Gibertini M; Whalen H; Reed CR
J Clin Psychiatry; 2009 Mar; 70(3):326-33. PubMed ID: 19284933
[TBL] [Abstract][Full Text] [Related]
30. Review of Allopregnanolone Agonist Therapy for the Treatment of Depressive Disorders.
Walkery A; Leader LD; Cooke E; VandenBerg A
Drug Des Devel Ther; 2021; 15():3017-3026. PubMed ID: 34267503
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and Safety of Duloxetine in Children and Adolescents with Major Depressive Disorder in Japan: A Randomized Double-Blind Placebo-Controlled Clinical Trial Followed by an Open-Label Long-Term Extension Trial.
Saito T; Ishida M; Nishiyori A; Ochiai T; Katagiri H; Matsumoto H
J Child Adolesc Psychopharmacol; 2022 Apr; 32(3):132-142. PubMed ID: 35319270
[No Abstract] [Full Text] [Related]
32. Acceptability, Tolerability, and Estimates of Putative Treatment Effects of Probiotics as Adjunctive Treatment in Patients With Depression: A Randomized Clinical Trial.
Nikolova VL; Cleare AJ; Young AH; Stone JM
JAMA Psychiatry; 2023 Aug; 80(8):842-847. PubMed ID: 37314797
[TBL] [Abstract][Full Text] [Related]
33. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
[TBL] [Abstract][Full Text] [Related]
34. Long-term Safety of Asenapine in Pediatric Patients Diagnosed With Bipolar I Disorder: A 50-Week Open-Label, Flexible-Dose Trial.
Findling RL; Landbloom RL; Mackle M; Wu X; Snow-Adami L; Chang K; Durgam S
Paediatr Drugs; 2016 Oct; 18(5):367-78. PubMed ID: 27461426
[TBL] [Abstract][Full Text] [Related]
35. Zuranolone as an oral adjunct to treatment of Parkinsonian tremor: A phase 2, open-label study.
Bullock A; Kaul I; Li S; Silber C; Doherty J; Kanes SJ
J Neurol Sci; 2021 Feb; 421():117277. PubMed ID: 33387701
[TBL] [Abstract][Full Text] [Related]
36. Once-Daily Crisaborole Ointment, 2%, as a Long-Term Maintenance Treatment in Patients Aged ≥ 3 Months with Mild-to-Moderate Atopic Dermatitis: A 52-Week Clinical Study.
Eichenfield LF; Gower RG; Xu J; Alam MS; Su JC; Myers DE; Sanders P; Vlahos B; Zang C; Lan J; Werth J
Am J Clin Dermatol; 2023 Jul; 24(4):623-635. PubMed ID: 37184828
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of escitalopram in treatment of severe depression in Chinese population.
Si T; Wang G; Yang F; Fang Y; Fang M; Li J; Dong J; Shen X; Zhuo J; Rui Q; Wang J; Cuili H
Metab Brain Dis; 2017 Jun; 32(3):891-901. PubMed ID: 28299626
[TBL] [Abstract][Full Text] [Related]
38. Safety and tolerability of vortioxetine (15 and 20 mg) in patients with major depressive disorder: results of an open-label, flexible-dose, 52-week extension study.
Jacobsen PL; Harper L; Chrones L; Chan S; Mahableshwarkar AR
Int Clin Psychopharmacol; 2015 Sep; 30(5):255-64. PubMed ID: 26020712
[TBL] [Abstract][Full Text] [Related]
39. Head-To-Head Comparison of Vortioxetine Versus Desvenlafaxine in Patients With Major Depressive Disorder With Partial Response to SSRI Therapy: Results of the VIVRE Study.
McIntyre RS; Florea I; Pedersen MM; Christensen MC
J Clin Psychiatry; 2023 May; 84(4):. PubMed ID: 37227402
[No Abstract] [Full Text] [Related]
40. Efficacy and safety of desvenlafaxine 50 mg/d for prevention of relapse in major depressive disorder:a randomized controlled trial.
Rosenthal JZ; Boyer P; Vialet C; Hwang E; Tourian KA
J Clin Psychiatry; 2013 Feb; 74(2):158-66. PubMed ID: 23473348
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
